The integration has established SyntheticMR as one unified company with a broader offering and a strengthened position in the growing neurodegenerative disease imaging segment.

cNeuro® cMRI has been integrated into SyntheticMR’s product portfolio, expanding the company’s capabilities in quantitative and AI-driven neuroimaging. Together with SyMRI®, the combined portfolio delivers comprehensive quantitative brain imaging solutions for patients with neurological disorders.

Following the acquisition, SyntheticMR has obtained regulatory approval in Europe for targeted updates to cNeuro® cMRI, including functionality for the automated detection of side effects associated with disease-modifying therapies for Alzheimer’s disease, known as ARIA (Amyloid-Related Imaging Abnormalities). This responds to emerging clinical needs driven by the increasing adoption of anti-amyloid therapies in Alzheimer’s disease.

As MRI imaging volumes rise, cNeuro® cMRI with automated ARIA detection supports clinicians by improving workflow efficiency, strengthening diagnostic confidence, and enabling faster identification of ARIA in clinical practice.

In parallel, cNeuro® cMRI has been introduced in the Indian market, leveraging its established SyMRI® presence to expand in a key growth region.

"The acquisition of Combinostics has enabled us to operate as one stronger organization with a broader portfolio." said Lena Åredal, CEO of SyntheticMR. "By aligning expertise across the company, we are strengthening our offering and positioning SyntheticMR as a leading provider of comprehensive solutions in neurodegenerative imaging."

SyntheticMR remains focused on innovation, regulatory expansion, and commercial execution to meet evolving clinical needs and drive sustainable long-term growth.

For additional information, please contact Lena Åredal, CEO, SyntheticMR AB, +46 76 770 99 08, lena.aredal@syntheticmr.com